product name Irsogladine
Description: Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder. It is used as an anti-gastric ulcer agent that facilitates gap-junctional intercellular communication through M1 muscarininc acetylcholine receptor binding. Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3%.
References: J Surg Res. 1998 Jul 1;77(2):126-31; Pancreas. 2002 Nov;25(4):373-7.
256.09
Formula
C9H7Cl2N5
CAS No.
57381-26-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 2 mg/mL (7.8 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19391594
| In Vitro |
In vitro activity: Irsogladine up-regulates GJIC between PC cells via regulation of the PKA pathway. It also suggests a useful adjuvant of Irsogladine to pancreatic cancer therapy. Irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46% (P < 0.05, p < 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice. |
| Animal model | |
| Formulation & Dosage | |
| References | J Surg Res. 1998 Jul 1;77(2):126-31; Pancreas. 2002 Nov;25(4):373-7; Life Sci. 2004 Aug 27;75(15):1833-42. |
Related Posts
product name Irsogladine
Description: Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder. It is used as an anti-gastric ulcer agent that facilitates gap-junctional intercellular communication through M1 muscarininc acetylcholine receptor binding. Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3%.
References: J Surg Res. 1998 Jul 1;77(2):126-31; Pancreas. 2002 Nov;25(4):373-7.
256.09
Formula
C9H7Cl2N5
CAS No.
57381-26-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 2 mg/mL (7.8 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19391594
| In Vitro |
In vitro activity: Irsogladine up-regulates GJIC between PC cells via regulation of the PKA pathway. It also suggests a useful adjuvant of Irsogladine to pancreatic cancer therapy. Irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46% (P < 0.05, p < 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice. |
| Animal model | |
| Formulation & Dosage | |
| References | J Surg Res. 1998 Jul 1;77(2):126-31; Pancreas. 2002 Nov;25(4):373-7; Life Sci. 2004 Aug 27;75(15):1833-42. |